Biosimilars Market By Product 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Biosimilars market
Biosimilars Market: By Product (Recombinant Glycosated Proteins and Others) Technology (mAbs, Chromatography, Mass Spectroscopy and Others); By Application (Blood & Oncology Diseases, Chronic Diseases and Others); By Geography-Forecast (2016 - 2021)
Report Code : HCR 0060
Published: 11 July, 2016   No. of pages: 152

  • Report Description
  • Table of Contents
  • Tables And Figures
  • Customization Options
Biosimilars are subsequent entry biologics (SEB) which are introduced into the market as the original biologic approaches patent expiry. Unlike the biologics, biosimilars are expressed in living cells which brings variability in the properties of the biosimilars. Hence, they possess properties similar to the biologic instead of being an exact copy of the original drug.

Biosimilars are emerging as one of the most important sector in the healthcare industry. With increasing healthcare costs, biosimilars are looked upon as an affordable treatment option. The report explains that global biosimilars market is segmented on the basis of product types, technology, application and geography.

Based on the technologies commercially available as biosimilars, the market is segmented as:
  • Monoclonal Antibodies Technology
  • Recombinant DNA Technology
  • Chromatography
  • Nuclear Magnetic Resonance Technology
  • Electrophoresis
  • Mass Spectrometry
  • Western Blotting
  • Bioassay

Based on product types, biosimilars are classified into Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides while their applications include Blood Disorders, Oncology Disease, Chronic and Autoimmune Diseases along with Growth Hormone Deficiency under Others category. Each of these segments is further broken down to give an in-depth analysis of the market across various applications and covers the market demand with respect to regions.

The Biosimilars market is driven by increased demand from the application sector such as blood disorders, oncology diseases, chronic diseases and many others. Economic turmoil in Europe is yet another factor which adds to the demand for biosimilars market. Reverse Innovation will drive down the overall development costs and hence, the high discounting on biosimilars will motivate the patient to opt for it in the long run.

Biosimilars Market

The developed markets such as the U.S. and Europe have been the forefront runner. Majority of drugs are currently being developed in these regions. In today’s emerging markets, biosimilars are still nascent, with little to no presence. The growing investor confidence, pressure to reduce costs and discounting is driving the market. On the contrary, lack of awareness and physician scepticism is acting as restraints. With respect to regulatory pathways, the system is in place for developed countries. Problem lies with countries such as China, India and Russia that are still trying to device the pathway.

The Key Players profiled in this report include like:
  • Novartis International AG
  • Hospira Inc.
  • Celltrion Pharma Inc.
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd.

Competitive analysis for biosimilars market is highlighted and market players are outlined and are examined on disparate aspects like company overview coupled with financial overview, product portfolio and recent developments.
1. Biosimilars– Market Overview
2. Executive Summary
3. Biosimilars – Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End user profiling
      3.2.3. Top 5 Financials Analysis
4. Biosimilars – Market Forces
   4.1. Market Drivers
      4.1.1. Economic turmoil in Europe driving demand for biosimilars
      4.1.2. 11 biologics to face patent expiration by 2020
      4.1.3. FDA keen on introducing more biosimilars into the market
      4.1.4. Asian companies have taken advantage by introducing low cost biosimilars
   4.2. Market Constraints and Challenges
      4.2.1. Stringent Regulatory Scenario
      4.2.2. Significant Developmental Cost
      4.2.3. Safety and Efficacy poses questions for physician while prescribing biosimilars
   4.3. Attractiveness of the Biosimilars Industry
      4.3.1. Power of Suppliers
      4.3.2. Power of Customers
      4.3.3. Threat of New entrants
      4.3.4. Threat of Substitution
      4.3.5. Degree of Competition
5. Biosimilars Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Biosimilars Market: By Type
   6.1. Recombinant Non-Glycosylated Proteins
   6.2. Recombinant Glycosylated Proteins
   6.3. Recombinant Peptides Others
7. Biosimilars Market – By Technology
   7.1. Monoclonal Antibodies Technology
   7.2. Recombinant DNA Technology
   7.3. Chromatography
   7.4. Nuclear Magnetic Resonance Technology
   7.5. Electrophoresis
   7.6. Mass Spectrometry
   7.7. Western Blotting
   7.8. Bioassay
8. Biosimilars Market – By Application
   8.1. Blood Disorders
   8.2. Oncology Diseases
   8.3. Chronic and Autoimmune Diseases
   8.4. Growth Hormone Deficiency
   8.5. Others
9. Biosimilars Market -Geographic Analysis
   9.1. Americas
      9.1.1. U.S.
      9.1.2. Canada
      9.1.3. Brazil
      9.1.4. Others
   9.2. Europe
      9.2.1. France
      9.2.2. Germany
      9.2.3. U.K.
      9.2.4. Italy
      9.2.5. Spain
      9.2.6. Others
   9.3. APAC
      9.3.1. China
      9.3.2. India
      9.3.3. Japan
      9.3.4. Australia
      9.3.5. Others
   9.4. ROW
10. Market Entropy
   10.1. New Product Launches
   10.2. M&As, Collaborations, JVs and Partnerships
11. Company Profiles
   11.1. HOSPIRA INC.
   11.2. STADA ARZNEIMITTEL AG
   11.3. NOVARTIS
   11.4. TEVA PHARMACEUTICAL COMPANY
   11.5. DR. REDDY’S LABORATORIES
   11.6. CELLTRION PHARMA
   11.7. BIOCON LIMITED
   11.8. MYLAN N.V.
   11.9. JOHNSON & JOHNSON
   11.10. DONG-A ST.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
List of Tables:

Table 1. Global Biosimilar Market Revenue, By Region, 2015-2021 ($Million)
Table 2. Global Biosimilar Market Volume, By Region, 2015-2021 (000’)
Table 3. Top Players Financials Analysis: By Companies, 2015 ($Million)
Table 4. Biosimilar Market Revenue By Technology (2015-2021) ($Million)
Table 5. Biosimilar Market Revenue Product Type (2015-2021) ($Million)
Table 6. Global Biosimilar Market Revenue, By Application, 2015-2021  ($Million)


List of Figures:

Figure 1. Biosimilars Market - By Technology
Figure 2. Biosimilar Market - By Product Type
Figure 3. Biosimilars Market - By Application
Figure 4. Biosimilars Market –By Geography
Figure 5. Biosimilar Drugs Under Development Process
Figure 6. Biosimilar Market Revenue, 2015-2022 ($Million)
Figure 7. Evolution of Biosimilar Drugs in the EU
Figure 8. Global Biosimilar Market Share, By  Product Type, 2015 (%)
Figure 9. Biosimilar Market Share Analysis, By Company 2015 (%)
Figure 10. Major Biologics Patent Expiration Scenario
Figure 11. Biosimilar Market, Porter’s Five Forces - Impacts
Figure 12. Biosimilar Market Porter’s Five Forces – Bargaining Power of Suppliers
Figure 13. Biosimilar Market Porter’s Five Forces – Bargaining Power of Buyers
Figure 14. Biosimilar Market Porter’s Five Forces – Threat of Substitution
Figure 15. Biosimilar Market Porter’s Five Forces – Threat of New Entrants
Figure 16. Biosimilar Market Porter’s Five Forces – Degree of Competition
Figure 17. Biosimilar Market Prices, By Region, 2015-2021
Figure 18. Pricing Trend in EU5 Countries Post Biosimilar Introduction
Figure 19. Biosimilar Market, Market Life Cycle, By Region
Figure 20. Biosimilar Market Life Cycle, 2015-2021
Figure 21. Biosimilar Market Regulatory Scenario in Europe
Figure 22. Biosimilar Market Regulatory Scenario in U.S.
Figure 23. Mono clonal Antibodies Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 24. Recombinant DNA Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 25. Chromatography Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 26. Nuclear Magnetic Resonance Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 27. Mass Spectrometry Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 28. Western Blotting Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 29. Bioassays Biosimilar Market Revenue, By Technology (2015-2021) ($Million)
Figure 30. Recombinant non-glycosylated Proteins Biosimilar Market Revenue, By Product Type (2015-2021) ($Million)
Figure 31. Recombinant glycosylated Proteins Biosimilar Market Revenue, By Product Type (2015-2021) ($Million)
Figure 32. Peptides Biosimilar Market Revenue, By Product Type (2015-2021) ($Million)
Figure 33. Blood Disorders Biosimilar Market Revenue, By Application (2015-2021) ($Million)
Figure 34. Oncology Diseases Biosimilar Market Revenue, By Application (2015-2021) ($Million)
Figure 35. Chronic And Autoimmune  Diseases Biosimilar Market Revenue, By Application (2015-2021) ($Million)
Figure 36. Growth Hormone Deficiency Biosimilar Market Revenue, By Application (2015-2021) ($Million)
Figure 37. Others Biosimilar Market Revenue, By Application (2015-2021) ($Million)
Figure 38. Hospira: Total Revenue, 2010-2014 , ($Billion)
Figure 39. Hospira: Total Sales, By Geography, 2014 (%)
Figure 40. Hospira: Total Sales, By Product Line, 2014 (%)
Figure 41. Stada Arzneimittel AG: Total Revenue, 2011-2015 , ($Billion)
Figure 42. Stada Arzneimittel AG: Total Sales, By Geography, 2015 (%)
Figure 43. Stada Arzneimittel AG: Total Sales, By Division, 2015 (%)
Figure 44. Novartis: Total Revenue, 2011-2015 ($Billion)
Figure 45. Novartis: Total Sales, By Geography, 2015 (%)
Figure 46. Novartis: Total Sales, By Division, 2015 (%)
Figure 47. TEVA: Total Revenue, 2011-2015 ($Billion)
Figure 48. TEVA: Total Sales, By Geography, 2015 (%)C
Figure 49. TEVA: Total Sales, By Division, 2015 (%)
Figure 50. Dr Reddy’s: Total Revenue, 2011-2015 ($Billion)
Figure 51. Dr Reddy’s: Total Sales, By Geography, 2015 (%)
Figure 52. Dr Reddy’s: Total Sales, By Division, 2015 (%)
Figure 53. Celltrion Pharma: Total Revenue, 2012-2015 ($Million)
Figure 54. Celltrion Pharma: Total Sales, By Division, 2015 (%)
Figure 55. Biocon: Total Revenue, 2011-2015 ($Million)
Figure 56. Biocon: Total Sales, By Geography, 2015 (%)
Figure 57. Biocon: Total Sales, By Division, 2015 (%)
Figure 58. Mylan: Total Revenue, 2011-2015 ($Billion)
Figure 59. Mylan: Total Sales, By Geography, 2015 (%)
Figure 60. Mylan: Total Sales, By Division, 2015 (%)
Figure 61. Johnson & Johnson: Total Revenue, 2011-2015 ($Billion)
Figure 62. Johnson & Johnson: Total Sales, By Geography, 2015 (%)
Figure 63. Johnson & Johnson: Total Sales, By Division, 2015 (%)
Figure 64. Dong-A ST: Total Sales, By Division, 2014 (%)
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports